In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer

Journal of Nuclear Medicine

Volumn 45, Issue 1, 2004, Pages 1-7

  Bennink, Roelof J ^a   Van Tienhoven, Geertjan ^a   Rijks, Leonie J ^a,b   Noorduyn, Arnold L ^a   Janssen, Anton G ^b   Sloof, Gerrit W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Breast cancer; Estrogen receptor; Radionuclide imaging; Tamoxifen

Indexed keywords

11BETA METHOXY 17ALPHA IODOVINYL ESTRADIOL I 123; ANTIESTROGEN; COMPLEMENT COMPONENT C1S; ESTROGEN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; 17 ALPHA IODOVINYL 11 BETA METHOXYESTRADIOL; 17 ALPHA-IODOVINYL-11 BETA-METHOXYESTRADIOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ESTRADIOL; RADIOPHARMACEUTICAL AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VINYL DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SCINTIGRAPHY; BREAST; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; BREAST; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAMOXIFEN; TREATMENT OUTCOME; VINYL COMPOUNDS;

EID: 1842556219     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Clark GM, Sledge GWJ, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
3. Rose C, Thorpe SM, Andersen KW, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet. 1985;325:16-19.
4. Bertelsen CA, Giuliano AE, Kern DH, Mann BD, Roe DJ, Morton DL. Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response. J Surg Res. 1984;37:257-263.
5. Wittliff JL. Steroid-hormone receptors in breast cancer. Cancer. 1984;53(3 suppl):630-643.
6. Merkel DE, Osborne CK. Use of steroid receptor assays in cancer management. Rev Endocrinol Rel Cancer. 1988;30:5-12.
7. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen Receptors in Human Breast Cancer. New York, NY: Raven Press; 1975:1-7.
8. McGuire WL, Horwitz KB, Pearson OH, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer. 1977;39(6 suppl):2934-2947.
9. van Netten JP, Armstrong JB, Carlyle SS, et al. Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers. Eur J Cancer Clin Oncol. 1988;24:1885-1889.
10. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer. 1983;52:479-485.
11. Castagnetta L, Traina A, Di Carlo A, Latteri AM, Carruba G, Leake RE. Heterogeneity of soluble and nuclear oestrogen receptor status of involved nodes in relation to primary breast cancer. Eur J Cancer Clin Oncol. 1987;23:31-35.
12. Mobbs BG, Fish EB, Pritchard KI, Oldfield G, Hanna WH. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol. 1987;23:819-826.
13. Van de Wiele C, De Vos F, Slegers G, Van Belle S, Dierckx RA. Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: a review. Eur J Nucl Med. 2000;27:1421-1433.
14. Katzenellenbogen JA. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med. 1995;36(6 suppl):8S-13S.
15. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
16. 18F]fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-1531.
17. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
18. Preston DF, Spicer JA, Baranczuk RJ, et al. Clinical results of breast cancer detection by imageable estradiol (I-123 E2) [abstract]. Eur J Nucl Med. 1990;16:430.
19. Schober O, Scheidhauer K, Jackisch C, et al. Breast cancer imaging with radioiodinated oestradiol [letter]. Lancet. 1990;335:1522.
20. 123I-labeled estradiol in breast cancer-receptor scintigraphy. Nuklearmedizin. 1991;30:84-99.
21. 123I]iodovinyl-11 beta- methoxyestradiol (MIVE2). Part II. Preliminary results in patients with breast carcinoma. Int J Rad Appl Instrum B. 1992;19:263-267.
22. 123I]iodovinylestradiol in healthy women and breast cancer patients. J Nucl Med. 1999;40:1728-1736.
23. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.
24. 123I]iodovinyloestradiol and its 11beta-methoxy derivative evaluated for their oestrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats. Eur J Nucl Med. 1996;23:295-307.
25. 123I]iodovinylestradiol is a promising radioligand for estrogen receptor imaging in human breast cancer. Nucl Med Biol. 1997;24:65-75.
26. Rijks LJ, Busemann SE, Stabin MG, de Bruin K, Janssen AG, van Royen EA. Biodistribution and dosimetry of iodine-123-labeled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging. Eur J Nucl Med. 1998;25:40-47.
27. Rijks LJ, Bakker PJ, van Tienhoven G, et al. Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE. J Clin Oncol. 1997;15:2536-2545.
28. Bennink RJ, Rijks LJ, van Tienhoven G, Noorduyn LA, Janssen AG, Sloof GW. Estrogen receptor status in primary breast cancer: iodine 123-labeled cis-11beta-methoxy-17alpha-iodovinyl estradiol scintigraphy. Radiology. 2001;220:774-779.
29. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003;42:361-372.
30. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977;39:1289-1294.
31. Sannino P, Shousha S. Demonstration of oestrogen receptors in paraffin wax sections of breast carcinoma using the monoclonal antibody 1D5 and microwave oven processing. J Clin Pathol. 1994;47:90-92.
32. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992;326:1756-1761.
33. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 2002;3:207-214.
34. Even-Sapir E, Keidar Z, Sachs J, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. J Nucl Med. 2001;42:998-1004.
35. 18F-fluoroestradiol (FES) PET [abstract]. J Nucl Med. 2000;41(suppl):28P.
36. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs. 2002;62:957-966.